Cost Effectiveness of Dose Optimized Ustekinumab Versus Switching to Anti-Tnfs Following Partial Response to Ustekinumab Every Twelve Weeks in Patients with Moderate to Severe Plaque Psoriasis
May 1, 2016, 00:00
10.1016/j.jval.2016.03.504
https://www.valueinhealthjournal.com/article/S1098-3015(16)00572-6/fulltext
Title :
Cost Effectiveness of Dose Optimized Ustekinumab Versus Switching to Anti-Tnfs Following Partial Response to Ustekinumab Every Twelve Weeks in Patients with Moderate to Severe Plaque Psoriasis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)00572-6&doi=10.1016/j.jval.2016.03.504
First page :
A124
Section Title :
Sensory System Disorders - Cost Studies
Open access? :
No
Section Order :
158